These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23281576)

  • 21. Leukocytosis and risk stratification assessment in essential thrombocythemia.
    Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
    J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
    Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
    Barbui T; Carobbio A; Rambaldi A; Finazzi G
    Blood; 2009 Jul; 114(4):759-63. PubMed ID: 19372254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
    Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Gangat N; Rambaldi A; Tefferi A; Barbui T
    Leukemia; 2012 Apr; 26(4):716-9. PubMed ID: 21926959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
    Abdulkarim K; Samuelsson J; Johansson P; Andréasson B
    Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.
    Gangat N; Strand J; Li CY; Wu W; Pardanani A; Tefferi A
    Br J Haematol; 2007 Aug; 138(3):354-8. PubMed ID: 17614822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
    Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
    Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC; Gómez M
    Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
    Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
    Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
    Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
    Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
    Johansson P
    Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
    Gianelli U; Iurlo A; Vener C; Moro A; Fermo E; Bianchi P; Graziani D; Radaelli F; Coggi G; Bosari S; Deliliers GL; Zanella A
    Am J Clin Pathol; 2008 Sep; 130(3):336-42. PubMed ID: 18701405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.
    Wolanskyj AP; Schwager SM; McClure RF; Larson DR; Tefferi A
    Mayo Clin Proc; 2006 Feb; 81(2):159-66. PubMed ID: 16471068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex and age as prognostic factors in essential thrombocythemia.
    Randi ML; Fabris F; Rossi C; Tison T; Barbone E; Girolami A
    Haematologica; 1992; 77(5):402-4. PubMed ID: 1483589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.